Adaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by Analysts at StockNews.com
StockNews.com initiated coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) in a research report released on Saturday morning. The brokerage issued a buy rating on the biotechnology company’s stock. Other analysts have also issued research reports about the company. Wells Fargo & Company cut their target price on Adaptimmune Therapeutics from $2.00 to […]
StockNews.com initiated coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) in a research report released on Saturday morning. The brokerage issued a buy rating on the biotechnology company’s stock. Other analysts have also issued research reports about the company. Wells Fargo & Company cut their target price on Adaptimmune Therapeutics from $2.00 to […]
